Beijing Winsunny Pharmaceutical CO.LTD Cash Flow-to-Debt Ratio
Beijing Winsunny Pharmaceutical CO.LTD cash flow-to-debt ratio. Beijing Winsunny Pharmaceutical CO.LTD (601089) has a Cash Flow-to-Debt Ratio of 0.55x as of December 2024, meaning its operating cash flow of CN¥690.75 Million could theoretically repay 1% of its total liabilities (CN¥1.26 Billion) in one year. Check earnings quality score of Beijing Winsunny Pharmaceutical CO.LTD to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Beijing Winsunny Pharmaceutical CO.LTD (2020–2024)
Cash flow-to-debt ratio of Beijing Winsunny Pharmaceutical CO.LTD from 2020 to 2024. Historical debt coverage capacity for Beijing Winsunny Pharmaceutical CO.LTD across 5 annual periods. Check 601089 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Beijing Winsunny Pharmaceutical CO.LTD Cash Flow-to-Debt Ratio by Year (2020–2024)
Beijing Winsunny Pharmaceutical CO.LTD cash flow-to-debt ratio by year from 2020 to 2024. Year-by-year debt coverage analysis for Beijing Winsunny Pharmaceutical CO.LTD. For the full cash flow conversion analysis, see 601089 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | CN¥690.75 Million | CN¥1.26 Billion | ▲ +5.6% |
| 2023 | 0.52x | CN¥555.90 Million | CN¥1.07 Billion | ▼ -10.1% |
| 2022 | 0.58x | CN¥659.76 Million | CN¥1.14 Billion | ▲ +2.5% |
| 2021 | 0.56x | CN¥528.02 Million | CN¥937.86 Million | ▲ +3.2% |
| 2020 | 0.55x | CN¥386.65 Million | CN¥709.01 Million | — |